Madhav V. Dhodapkar, MBBS

Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Chief, Section of Hematology, Department of Internal Medicine; Clinical Research Program Leader, Hematology Program, Yale Cancer Center

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program

Hematology

National Gaucher Disease Treatment Center

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1994)

  • Medical Oncology AB of Internal Medicine (1995)

Clinical Trials

Conditions Study Title
Multiple Myeloma Immunology and Pathobiology of Plasma Cell Disorders
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Bones and Joints Correlation Between Macrophage Fusion and Severity of GVHD
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Leukemia, other A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia
Multiple Myeloma A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Edit this profile

Contact Info

Madhav V. Dhodapkar, MBBS
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavillion 7

New Haven, CT 06510
Mailing Address
PO Box 208028
333 Cedar Street, TMP 3

New Haven, CT 06520-8028